Top Markets
Coin of the day
Curatis Holding AG Curatis Holding AG

Curatis Holding AG

CURN
Classifica tra le azioni #20295
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical... Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.
Prezzo delle azioni
$25.36
Capitalizzazione di mercato
$134.44M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
84.00%
Paese
CH
Scambia Curatis Holding AG (CURN)

Categoria

Storico del prezzo dell'azione per Curatis Holding AG (CURN)
Prezzo di chiusura più alto: $25.29 il 2026-08-01

Prezzo di chiusura più basso: $1.26M il 1999-04-01
Storico del prezzo dell'azione di Curatis Holding AG dal 1999 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 54.44%
2025 2.02%
2024 524.76%
2023 -95.88%
2022 -83.81%
2021 -17.34%
2020 481.84%
2019 37.23%
2018 -52.65%
2017 -17.39%
2016 -30.62%
2015 -47.06%
2014 -44.60%
2013 13.03%
2012 8.19%
2011 -47.25%
2010 -0.13%
2009 146.64%
2008 -94.83%
2007 -25.49%
2006 -36.45%
2005 -14.30%
2004 -19.20%
2003 8.14%
2002 88.71%
2001 -91.53%
2000 -89.36%
1999 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$171.67 -
DE
$164.46 25.10%
DE
$37.82 21.13%
JP
$222.79 32.01%
CH
$21.08 12.12%
IN